Cost of Revenue Comparison: AstraZeneca PLC vs Geron Corporation

AstraZeneca vs. Geron: A Decade of Cost Dynamics

__timestamp	AstraZeneca PLC	Geron Corporation
Wednesday, January 1, 2014	5842000000	8901000
Thursday, January 1, 2015	4646000000	9574000
Friday, January 1, 2016	4126000000	14695000
Sunday, January 1, 2017	4318000000	8437000
Monday, January 1, 2018	4936000000	12723000
Tuesday, January 1, 2019	4921000000	51272000
Wednesday, January 1, 2020	5299000000	50052000
Friday, January 1, 2021	12437000000	783000
Saturday, January 1, 2022	12391000000	868000
Sunday, January 1, 2023	8040000000	123740000
Monday, January 1, 2024	10207000000

In pursuit of knowledge

Cost of Revenue: AstraZeneca PLC vs. Geron Corporation

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This analysis compares the cost of revenue for AstraZeneca PLC and Geron Corporation from 2014 to 2023. AstraZeneca, a global leader, consistently shows a robust cost of revenue, peaking in 2021 with a staggering 124% increase from 2016. In contrast, Geron Corporation, a smaller biotech firm, exhibits a more volatile pattern, with a notable spike in 2023, reaching a cost of revenue over 1,200% higher than its 2021 low. This disparity highlights the scale and operational differences between a pharmaceutical giant and a niche biotech player. The data underscores AstraZeneca's steady growth and Geron's fluctuating financial landscape, offering insights into their strategic priorities and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025